Bioventus (BVS) investor relations material

Executive summary

• Q3 net sales rose 2.7% to $142.442 million; nine-month sales increased 4.3% to $427.739 million, led by Pain Treatments and international markets.

• Q3 Adjusted EBITDA was $28.356 million, up from $26.604 million; Adjusted EBITDA margin reached 20%, up 70 bps YoY.

• Strategic alternatives review continued following an unsolicited acquisition proposal and other expressions of interest; outcomes and timing remain uncertain.

Financial highlights

• Net income attributable to Bioventus Inc. was $5.987 million versus $3.155 million YoY; GAAP diluted EPS was $0.08 versus $0.05.

• Adjusted EBITDA was $28.356 million versus $26.604 million; non-GAAP diluted EPS was $0.17 versus $0.15, up 13% YoY.

• Nine-month Adjusted EBITDA was $87.534 million versus $79.567 million; nine-month net income included a $26.927 million income tax benefit from a valuation allowance release.

• GAAP gross profit was $97 million versus $94 million, with gross margin of 68.2% versus 68.0%; operating income was $9.700 million versus $11.252 million.

• Adjusted gross margin was 74.7%, down 50 bps YoY, primarily due to product mix.

Outlook and guidance

• FY 2026 net sales guidance was updated to $590 million–$595 million, reflecting lower expectations primarily in BGS; Q4 growth is expected to accelerate sequentially to mid-single digits.

• FY 2026 Adjusted EPS guidance was reaffirmed at $0.75–$0.79 per diluted share; Adjusted EBITDA margin is expected to exceed the prior-year level.

• Adjusted Cash from Operations guidance is $84 million–$89 million, excluding cash costs related to the strategic alternatives review.

• International revenue is expected to grow more than 20% in Q4; EXOGEN growth is expected in the low single digits in 2026, while PNS is expected to scale above $100 million in the coming years.